Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza reported a small open-market sale of 774 Ordinary Shares. The shares were sold at a weighted average price of $5.3795 per share on June 22, 2026, and he held 310,684 shares afterward.
According to the disclosure, the sale was made to cover tax withholding obligations from restricted stock units that vested on June 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary.
SOPHiA GENETICS SA President Ross Muken reported an open-market sale of 422 Ordinary Shares at a weighted average price of $5.3803 per share. According to the disclosure, the shares were sold in the open market solely to satisfy tax withholding obligations tied to the vesting of restricted stock units on June 18, 2026, under a pre-established Rule 10b5-1(c) trading plan and were not discretionary trades. Following this small, tax-related transaction, he directly holds 680,489 Ordinary Shares.
SOPH affiliate filed a Form 144 notifying a proposed sale of 774 shares of Common Stock issuable upon Restricted Stock Units dated 06/18/2026. The excerpt also lists prior 10b5-1 dispositions of Common shares on 04/06/2026, 04/07/2026, and 04/08/2026, with per-trade share counts shown.
Ross J Muken reported multiple 10b5-1 dispositions of Common Stock via Form 144, listing specific sale dates, share counts, and proceeds. The filing also lists Restricted Stock Units dated 06/18/2026.
The excerpt shows sale entries including 05/19/2026 (761 shares for $3,501.06), 04/13/2026 (4,442 shares for $21,166.13), and several April 2026 trades. Broker information lists Morgan Stanley Smith Barney LLC Executive Financial Services.
SOPHiA GENETICS SA director Troy Cox received new equity awards tied to his board service. He was granted 19,724 restricted stock units, each representing one ordinary share valued at $5.46, bringing his direct holdings to 328,743 ordinary shares.
He also received options to purchase 28,818 ordinary shares at an exercise price of $5.46 per share, expiring on June 18, 2036, increasing his option holdings to 252,809. Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, contingent on his continued service.
SOPHiA GENETICS SA director Kathy L. Hibbs received new equity awards as part of her compensation. She was granted 19,724 restricted stock units, each representing one ordinary share, at a reference price of $5.46 per share. Following this award, she directly holds 109,492 ordinary shares.
She also received options to buy 28,818 ordinary shares at an exercise price of $5.46 per share, expiring on June 18, 2036, bringing her total option holdings to 218,569 share options. Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to her continued service.
SOPHiA GENETICS SA director Vincent Ossipow received equity compensation consisting of restricted stock units and options. On June 18, 2026 he was granted 19,724 RSUs, each representing one ordinary share, and 28,818 share options with a $5.46 exercise price. Both the RSUs and options vest 100% at the date of the company’s next scheduled annual shareholder meeting, subject to his continued service. Following these awards, he directly holds 522,860 ordinary shares and 138,569 options.
SOPHiA GENETICS SA director Jean-Michel Cossery reported receiving new equity awards as part of his compensation. He was granted 19,724 restricted stock units, each representing one ordinary share, and 28,818 share options with a conversion price of $5.46 per share.
Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to his continued service. Following these awards, Cossery directly holds 206,212 ordinary shares and 138,449 options.
SOPHiA GENETICS SA director Didier Hirsch received new equity awards as part of his compensation. He was granted 19,724 Ordinary Shares in the form of restricted stock units valued at $5.46 per share, bringing his direct share holdings to 240,220 Ordinary Shares.
He also received options to buy 28,818 Ordinary Shares at an exercise price of $5.46 per share, with 218,569 options held after the grant. Both the RSUs and the options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to his continued service.
SOPHiA GENETICS completed an underwritten public offering of 12,104,900 ordinary shares at $4.75 per share, raising gross proceeds of about $57.5 million before fees and expenses. The deal included 1,578,900 additional shares sold after underwriters fully exercised their option, and closed on June 18, 2026.
The shares were issued under an effective Form F-3 shelf registration, with TD Securities leading a syndicate of underwriters. All shares were sold by the company, providing new primary capital and diluting existing shareholders while strengthening the balance sheet.